Primary Retroperitoneal Lymph Node Dissection in Stage I and Low-volume Metastatic Germ Cell Tumors.

Eur Urol Focus

USC Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address:

Published: March 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Testicular germ cell tumors (GCTs) are the most common malignancy among young males. The majority of patients present with early stages of the disease that are highly curable. For stage I disease, treatment options include surveillance, retroperitoneal lymph node dissection (RPLND), and systemic chemotherapy. For stage II disease, systemic therapy had been the mainstay of treatment. However, it has recently been shown that primary RPLND is effective as a treatment for low-volume metastatic GCT and offers the benefit of avoiding chemotherapy in young men at risk of suffering the long-term sequelae of systemic treatments. In this narrative mini-review, we evaluate the data on primary RPLND for the management of stage I and low-volume metastatic GCT. PATIENT SUMMARY: This mini-review discusses the role of surgery involving removal of retroperitoneal lymph nodes for stage I and low-volume stage II testicular cancer. We found that for well-selected patients, surgery can be curative in the majority of cases and avoids the risks associated with systemic chemotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2023.01.007DOI Listing

Publication Analysis

Top Keywords

retroperitoneal lymph
12
stage low-volume
12
low-volume metastatic
12
lymph node
8
node dissection
8
germ cell
8
cell tumors
8
stage disease
8
systemic chemotherapy
8
primary rplnd
8

Similar Publications

Introduction: Metastatic colorectal cancer (mCRC) exhibits significant heterogeneity in molecular profiles, influencing treatment response and patient outcomes. Mutations in v-raf murine sarcoma viral oncogene homolog B1 () and rat sarcoma () family genes are commonly observed in mCRC. Though originally thought to be mutually exclusive, recent data have shown that patients may present with concomitant and mutations, posing unique challenges and implications for clinical management.

View Article and Find Full Text PDF

Cancer of the ovary, fallopian tube, and peritoneum: 2025 update.

Int J Gynaecol Obstet

September 2025

Stanford Women's Cancer Center, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA.

In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSCs). Stage IC is now divided into three categories: IC1 (surgical spill), IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface), and IC3 (malignant cells in the ascites or peritoneal washings).

View Article and Find Full Text PDF